Perspective Therapeutics, Inc. (NYSE:CATX) Receives $15.13 Consensus PT from Analysts

Perspective Therapeutics, Inc. (NYSE:CATX) has received a consensus rating of “Buy” from the eleven ratings firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, seven have given a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $15.13.

CATX has been the topic of a number of recent research reports. Lifesci Capital raised Perspective Therapeutics to a “strong-buy” rating in a research note on Thursday, March 6th. Brookline Capital Management upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a research report on Monday. Wedbush reaffirmed an “outperform” rating and set a $11.00 price target on shares of Perspective Therapeutics in a report on Friday, January 24th. Scotiabank initiated coverage on Perspective Therapeutics in a research note on Friday, March 7th. They issued a “sector outperform” rating and a $15.00 price target for the company. Finally, Cantor Fitzgerald raised shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CATX. Y Intercept Hong Kong Ltd acquired a new stake in shares of Perspective Therapeutics during the 4th quarter worth about $33,000. Aigen Investment Management LP acquired a new position in shares of Perspective Therapeutics in the fourth quarter worth $34,000. National Bank of Canada FI raised its position in Perspective Therapeutics by 549,900.0% in the 4th quarter. National Bank of Canada FI now owns 11,000 shares of the company’s stock valued at $35,000 after purchasing an additional 10,998 shares in the last quarter. ProShare Advisors LLC lifted its stake in Perspective Therapeutics by 49.1% in the fourth quarter. ProShare Advisors LLC now owns 15,225 shares of the company’s stock worth $49,000 after acquiring an additional 5,011 shares during the last quarter. Finally, Vontobel Holding Ltd. purchased a new position in Perspective Therapeutics in the fourth quarter valued at $51,000. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Trading Up 6.4 %

NYSE CATX opened at $2.66 on Monday. The stock has a 50 day simple moving average of $3.17 and a two-hundred day simple moving average of $7.44. Perspective Therapeutics has a fifty-two week low of $2.32 and a fifty-two week high of $19.05.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.